Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest & Investment Income (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Interest & Investment Income for 16 consecutive years, with $294.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 79.86% year-over-year to $294.0, compared with a TTM value of $3125.0 through Sep 2025, down 60.12%, and an annual FY2024 reading of $6641.0, up 0.59% over the prior year.
  • Interest & Investment Income was $294.0 for Q3 2025 at China Pharma Holdings, down from $422.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $6655.0 in Q1 2022 and bottomed at $294.0 in Q3 2025.
  • Average Interest & Investment Income over 5 years is $1517.0, with a median of $1240.0 recorded in 2022.
  • The sharpest move saw Interest & Investment Income soared 1539.16% in 2022, then crashed 85.76% in 2023.
  • Year by year, Interest & Investment Income stood at $1412.0 in 2021, then decreased by 28.97% to $1003.0 in 2022, then surged by 152.24% to $2530.0 in 2023, then tumbled by 47.23% to $1335.0 in 2024, then plummeted by 77.98% to $294.0 in 2025.
  • Business Quant data shows Interest & Investment Income for CPHI at $294.0 in Q3 2025, $422.0 in Q2 2025, and $1074.0 in Q1 2025.